Antiplatelet Therapy: Role of Effient® (prasugrel)

 | 

A Best Practices supplement to Internal Medicine News. This promotional supplement was supported by Daiichi-Sankyo, Inc. and Eli Lilly and Company.

Antiplatelet Therapy: Role of Effient® (prasugrel)

•Topics
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

TOPIC HIGHLIGHTS

• Introduction
• Clinical Pharmacology
• TRITON-TIMI 38
• Bleeding
• Application of TRITON-TIMI 38 to Clinical Practice
• Conclusion
• Effient Important Safety Information

 

FACULTY/FACULTY DISCLOSURE

Roxana Mehran, MD
Director of Interventional Cardiovascular Research and Clinical Trials
Zena and Michael A. Wiener Cardiovascular Institute
Mount Sinai School of Medicine
Professor of Medicine
Mount Sinai School of Medicine
Chief Scientific Officer
Clinical Trials Center
Cardiovascular Research Foundation
New York, NY

Dr Mehran receives grant support from sanofi-aventis/Bristol-Myers Squibb and is a consultant for Abbott Vascular, Accumetrics, Cardiva, and The Medicines Company and is a paid consultant to Daiichi Sankyo, Inc. and Lilly USA, LLC.

Benjamin Z. Galper, MD, MPH
Medical Resident
Department of Medicine
New York Presbyterian Hospital/Columbia University Medical Center
New York, NY

Dr Galper is a paid consultant of Daiichi Sankyo, Inc. and Lilly USA, LLC.

George D. Dangas, MD, PhD
Director of Cardiovascular Innovation
Zena and Michael A. Wiener Cardiovascular Institute
Mount Sinai School of Medicine
Professor of Medicine
Mount Sinai School of Medicine
Director, Academic Affairs
Cardiovascular Research Foundation
New York, NY

Dr Dangas is a consultant for AstraZeneca and Cordis Corp. (a Johnson & Johnson Company) and a paid consultant to
Daiichi Sankyo, Inc. and Lilly USA, LLC.

Copyright © 2010 Elsevier Inc.

---